ArticleInternational journal of women's health2025
Exploring the Potential Causal Relationship of Galectin Levels and Gynecologic Cancers: A Two-Sample Mendelian Randomization Study.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic Performance of Galectin-1 and Mucin-1 in Uterine Tumors: A Case-Control Study.Current issues in molecular biology · 2026Article
- Mendelian Randomization to Examine the Causal Effects of Cystatin on Ovarian Lesions.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have reported the correlation between single galectin levels and gynecologic cancers. The present study used the Mendelian randomization (MR) technique to evaluate the causal relationship between galectin levels and gynecologic cancers. Methods: Data on galectin levels (3394 individuals of the Gal-3 dataset, 3301 individuals of Gal-1, Gal-2, Gal-4, Gal-7, Gal-8, Gal-9, and Gal-10 datasets) and gynecologic cancers were obtained from the IEU Open genome-wide association study (GWAS) project, Ovarian Cancer Association Consortium (OCAC) and FinnGen consortium. Two-sample MR was performed to determine the causal relationship between galectin levels and gynecologic cancers. Meanwhile, a bi-directional MR analysis was also conducted to examine the direction of the causal relations. The results were expressed as odds ratios (ORs) and 95% confidence intervals (CIs). Results: Gal-3 (OR=1.001, 95% CI: 1.000-1.001) and Gal-8 (OR=1.001, 95% CI: 1.000-1.002) may indicate small effects on cervical cancer. Gal-1 was suggested as risk factors for ovarian cancer (OR=1.108, 95% CI: 1.033-1.188), high grade serous ovarian cancer (OR=1.106, 95% CI: 1.019-1.202), and invasive mucinous ovarian cancer (OR=1.279, 95% CI: 1.041-1.573). Gal-9 showed modest effect in ovarian cancer (OR=1.070, 95% CI: 1.000-1.144), but significantly associated with an elevated risk of mucinous ovarian cancer (OR=1.242, 95% CI: 1.015-1.520). Gal-10 was suggested as a protective factor against ovarian cancer (OR=0.929, 95% CI: 0.867-0.994) and clear cell ovarian cancer (OR=0.803, 95% CI: 0.653-0.987). Gal-2 (OR=0.779, 95% CI: 0.654-0.929) and Gal-4 (OR=0.786, 95% CI: 0.639-0.966) were found as protective factors for malignant neoplasm of corpus uteri. Gal-2 (OR=0.921, 95% CI: 0.851-0.997) and Gal-10 (OR=0.892, 95% CI: 0.815-0.977) were suggested as protective factors against endometrial cancer (endometrioid histology). Similarly, higher Gal-4 was also associated with decreased risk of endometrial cancer (OR=0.902, 95% CI: 0.840-0.969) and endometrial cancer (endometrioid histology) (OR=0.846, 95% CI: 0.778-0.920). Conclusion: The study explored potential causal relationships between galectin levels and gynecologic cancers. While some associations were modest, the consistent directionality across sensitivity analyses and the biological plausibility of galectins in tumor immunology suggest that these proteins warrant further investigation as potential biomarkers and therapeutic targets. Future research should validate these findings in clinical cohorts and explore underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.